Suppliers and packagers for generic pharmaceutical drug: MARAVIROC

MARAVIROC

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Viiv Hlthcare	SELZENTRY	maraviroc	SOLUTION;ORAL	208984	NDA	ViiV Healthcare Company	49702-260-55	1 KIT in 1 CARTON (49702-260-55) * 230 mL in 1 BOTTLE	2020-10-30
Hetero Labs Ltd Iii	MARAVIROC	maraviroc	TABLET;ORAL	203347	ANDA	Camber Pharmaceuticals, Inc.	31722-579-60	60 TABLET, FILM COATED in 1 BOTTLE (31722-579-60)	2022-02-06
Hetero Labs Ltd Iii	MARAVIROC	maraviroc	TABLET;ORAL	203347	ANDA	Camber Pharmaceuticals, Inc.	31722-580-60	60 TABLET, FILM COATED in 1 BOTTLE (31722-580-60)	2022-02-06

Maraviroc API and Intermediate Suppliers

Last updated: February 19, 2026

This report details key suppliers of Maraviroc active pharmaceutical ingredient (API) and critical intermediates, relevant for R&D and investment decisions within the pharmaceutical sector. The analysis focuses on manufacturing capabilities, regulatory standing, and patent landscape implications.

Who are the Primary Manufacturers of Maraviroc API?

Several entities globally possess the technical expertise and regulatory approvals to manufacture Maraviroc API. These suppliers range from established contract development and manufacturing organizations (CDMOs) to specialized API producers. Key players include:

• Divi's Laboratories: A significant player in API manufacturing, Divi's has demonstrated capabilities in complex synthesis. They are known for their large-scale production capacity and adherence to stringent quality standards. Their involvement in Maraviroc supply suggests a robust understanding of its manufacturing process.
• Laurus Labs: This Indian-based pharmaceutical company is a major producer of APIs and has a strong portfolio in antiviral and anti-HIV therapeutics. Laurus Labs' expertise in process chemistry and cGMP compliance makes them a likely candidate for Maraviroc API supply.
• Hetero Drugs: Another prominent Indian pharmaceutical firm, Hetero Drugs operates a substantial API manufacturing division. They are recognized for their backward integration and capacity to produce a wide range of APIs, including those for complex therapeutic areas.

The landscape of Maraviroc API manufacturing is characterized by a concentration of producers in regions with established pharmaceutical manufacturing infrastructure, particularly India and, to a lesser extent, China. Companies operating in these regions often leverage cost efficiencies alongside strong technical capabilities.

What are the Critical Intermediates in Maraviroc Synthesis?

The synthesis of Maraviroc involves several key intermediates, the reliable supply of which is crucial for API manufacturers. Disruptions in intermediate availability can directly impact API production timelines and costs. Identifying the sources and stability of these intermediates is essential for supply chain risk assessment.

Key intermediates include:

• 1-adamantyl cyclohexyl derivative: This is a foundational building block for the Maraviroc molecule. Its synthesis requires specific stereochemical control and purity.
• Fluorobenzyl derivative: This component introduces the crucial fluorine atom, impacting the drug's pharmacokinetic properties. The precise regiochemistry of fluorination is critical.
• Piperidine derivative: The piperidine ring is a core structural element. Its incorporation requires efficient coupling reactions.

Suppliers of these intermediates often operate as specialized chemical manufacturers, some of whom may also produce APIs. The complexity of these intermediates means that sourcing often involves companies with advanced organic synthesis capabilities. For instance, companies focusing on fluorinated compounds or complex heterocyclic chemistry are more likely to be involved in supplying these specific building blocks.

Table 1 lists representative intermediates and their general significance in Maraviroc synthesis.

Intermediate Type	Chemical Significance in Maraviroc Synthesis
Adamantane-based precursor	Forms the core tricyclic structure of Maraviroc.
Fluorinated aromatic compound	Contributes to receptor binding affinity and metabolic stability.
Substituted piperidine derivative	Essential for the CCR5 antagonist activity by interacting with the receptor.
Chiral auxiliary or starting material	Crucial for establishing the correct stereochemistry of the final API.

What is the Patent Landscape Surrounding Maraviroc Manufacturing?

The patent landscape for Maraviroc is primarily defined by patents protecting the compound itself and its methods of use. However, process patents covering novel or improved synthesis routes are also significant for API manufacturers.

The originating patent for Maraviroc (Selzentry, Celsentri) is held by ViiV Healthcare, a joint venture between GSK and Pfizer. Key patents relating to Maraviroc include:

• Composition of Matter Patents: These patents claim the Maraviroc molecule itself. The initial broad patents for Maraviroc have largely expired in major markets, opening opportunities for generic manufacturers. For example, the primary composition of matter patent in the U.S. expired around 2019-2020.
• Method of Use Patents: These patents claim specific therapeutic uses of Maraviroc, such as for treating HIV infection. The expiry of these patents also influences market dynamics.
• Process Patents: ViiV Healthcare and other entities may hold patents on specific, efficient, or novel synthetic routes to Maraviroc. These patents can provide a competitive advantage by protecting a more cost-effective or environmentally friendly manufacturing process. Generic manufacturers must either design around these process patents or seek licenses.

The expiry of key composition of matter and method of use patents has facilitated the entry of generic Maraviroc products. This has, in turn, increased demand for Maraviroc API from a broader base of pharmaceutical companies. However, potential infringement of existing or newly filed process patents remains a consideration for API manufacturers.

The U.S. Patent and Trademark Office (USPTO) and the European Patent Office (EPO) are key jurisdictions for tracking Maraviroc-related patents. Companies intending to manufacture or market Maraviroc must conduct thorough freedom-to-operate (FTO) analyses.

What are the Regulatory Requirements for Maraviroc API Production?

Production of Maraviroc API must adhere to strict regulatory guidelines to ensure safety, efficacy, and quality. Compliance with current Good Manufacturing Practices (cGMP) is mandatory for API manufacturers supplying to regulated markets.

Key regulatory aspects include:

• cGMP Compliance: Manufacturers must operate under cGMP guidelines as established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national authorities. This encompasses quality control, documentation, facility standards, and personnel training.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. The DMF allows regulatory agencies to review proprietary information without disclosure to the drug product applicant.
• Inspections and Audits: Facilities are subject to regular inspections by regulatory authorities and audits by pharmaceutical companies purchasing the API. Successful inspection outcomes are critical for maintaining supply relationships.
• Impurity Profiling: Rigorous control and characterization of impurities are essential. The identification, qualification, and quantification of process-related impurities and potential degradants must meet pharmacopoeial standards (e.g., USP, EP) and ICH guidelines.

Companies like Divi's Laboratories, Laurus Labs, and Hetero Drugs typically have well-established quality management systems and a history of successful regulatory inspections, making them reliable suppliers in this regard.

How Does the Generic Market Impact Maraviroc API Demand?

The expiration of core patents for Maraviroc has led to the development and launch of generic versions of the drug. This has significantly altered the market dynamics and increased demand for Maraviroc API.

Key impacts of the generic market:

• Increased Volume Demand: Generic competition typically drives down the price of the finished drug product, leading to increased patient access and, consequently, higher overall demand for the API.
• Price Pressure: Generic manufacturers operate on tighter margins, which translates to increased price pressure on API suppliers. This necessitates efficient manufacturing processes and economies of scale.
• Supplier Diversification: As more companies enter the generic Maraviroc market, they seek to diversify their API supply chains to mitigate risks and secure competitive pricing. This benefits established and emerging API manufacturers.
• Quality and Cost Competition: The generic market intensifies competition based on both API quality (meeting regulatory standards) and cost-effectiveness. Manufacturers with robust quality systems and efficient processes are best positioned.

The growth of the generic Maraviroc market suggests sustained or increasing demand for Maraviroc API from multiple global pharmaceutical companies aiming to capture market share in the antiretroviral therapy segment.

What are the Supply Chain Risks Associated with Maraviroc Production?

The production of complex APIs like Maraviroc is susceptible to various supply chain risks. Identifying and mitigating these risks is paramount for ensuring consistent drug availability.

Potential risks include:

• Raw Material Sourcing: Dependence on a limited number of suppliers for key starting materials or intermediates can create vulnerabilities. Geopolitical instability, natural disasters, or quality issues with a single raw material supplier can disrupt the entire production chain.
• Manufacturing Site Concentration: If a significant portion of Maraviroc API or critical intermediate production is concentrated in a single geographical region or a few manufacturing sites, disruptions due to regulatory actions, labor disputes, or unforeseen events can have widespread consequences.
• Regulatory Hurdles: Unexpected regulatory changes, delays in approvals, or cGMP non-compliance issues at a manufacturing site can halt API production and supply.
• Intellectual Property Disputes: While primary patents may have expired, ongoing litigation or new filings related to process patents can create uncertainty and potential supply disruptions if a manufacturer is found to be infringing.
• Logistical Challenges: Global supply chains are subject to shipping delays, customs issues, and fluctuating transportation costs, which can impact the timely delivery of both raw materials and finished API.

For Maraviroc, given its complex synthesis, reliance on specific chemical precursors sourced globally, and the concentration of manufacturing in certain regions, proactive supply chain management is essential. This includes qualifying multiple suppliers for critical components and maintaining strong relationships with manufacturers who demonstrate robust quality and business continuity plans.

Key Takeaways

• Maraviroc API manufacturing is dominated by established players in India, including Divi's Laboratories, Laurus Labs, and Hetero Drugs, known for their cGMP compliance and large-scale production capacities.
• Critical intermediates in Maraviroc synthesis require specialized chemical manufacturing expertise, with a focus on adamantane derivatives, fluorinated aromatics, and piperidine compounds.
• The patent landscape for Maraviroc is evolving, with the expiration of core composition of matter patents facilitating generic entry, while process patents remain a consideration for API manufacturers.
• Regulatory compliance, particularly cGMP, is a non-negotiable requirement for API suppliers, necessitating robust quality management systems and successful regulatory inspections.
• The growth of the generic Maraviroc market is driving increased API volume demand and intensifying competition on both quality and cost.
• Supply chain risks, including raw material sourcing, manufacturing site concentration, and regulatory challenges, require careful management to ensure consistent Maraviroc API availability.

Frequently Asked Questions

1. What is the primary therapeutic use of Maraviroc? Maraviroc is an antiretroviral medication used in the treatment of human immunodeficiency virus (HIV) infection. It acts as a CCR5 antagonist, preventing the virus from entering human cells.

2. Which regulatory bodies are most critical for Maraviroc API suppliers to comply with? Suppliers must primarily comply with the regulations of the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and equivalent national regulatory authorities in the target markets for the finished drug product.

3. Are there any specific challenges in synthesizing the chiral centers of Maraviroc? Yes, Maraviroc has chiral centers that require precise stereochemical control during synthesis to ensure the correct enantiomer is produced, which is crucial for pharmacological activity and safety.

4. How does the origin country of API manufacturing influence its regulatory acceptance? Regulatory acceptance is based on the manufacturer's adherence to cGMP standards, regardless of the country of origin. However, regulatory agencies conduct inspections in various regions, and a history of successful inspections in a particular region is often noted.

5. What is the typical shelf life of Maraviroc API? The typical shelf life of Maraviroc API, when stored under recommended conditions, is generally two to three years, subject to specific stability data and pharmacopoeial requirements.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA website for DMF information]

[2] European Medicines Agency. (n.d.). Active substances (AS). Retrieved from [EMA website for AS information]

[3] ViiV Healthcare. (n.d.). Selzentry® (maraviroc) prescribing information.

[4] U.S. Patent and Trademark Office. (n.d.). Patent Search.

[5] European Patent Office. (n.d.). Espacenet patent database.